Millions of people over 50 take medication for osteoporosis, and a large share of them are in the years when dental implants come up. Many have heard that these drugs and jaw surgery do not mix, usually in the form of a warning about a condition with a long name that sounds catastrophic. Some have been declined for implants on that basis. Some have stopped their medication without telling their physician in order to qualify, which is a worse outcome than either.
The reality is more measured. Osteoporosis drugs do change how the jaw heals, the serious complication is real, and its risk depends heavily on which drug you take, how you take it, and for how long. For most patients on oral bisphosphonates for osteoporosis, the risk is low and implants are placed routinely with precautions. For patients on high-dose intravenous versions for cancer, it is a different conversation.
This guide explains what the drugs do, what the complication is, how the risk varies, and how surgeons handle it.
What do osteoporosis medications do to the jawbone?
Bisphosphonates such as alendronate, risedronate, ibandronate, and zoledronic acid, and the antibody drug denosumab, slow the cells that break down old bone. That is how they treat osteoporosis: less bone is removed, so density rises. The same effect slows bone remodeling in the jaw, which is the process that heals a surgical site and integrates an implant. Bone that cannot remodel normally heals more slowly and, in rare cases, fails to heal at all.
What is osteonecrosis of the jaw, and how likely is it?
Medication-related osteonecrosis of the jaw, usually shortened to MRONJ, is an area of jawbone that dies and becomes exposed through the gum after a trigger such as an extraction or implant surgery, and does not heal. It is painful, difficult to treat, and the reason surgeons ask about these drugs. It is also uncommon in osteoporosis patients on oral medication, with estimates in the range of a fraction of one percent, and much more common in cancer patients receiving high-dose intravenous bisphosphonates or denosumab, where estimates run into the low single-digit percent range.
The distinction between those two groups is the most important fact in this guide. Osteoporosis patients on standard oral doses are low risk. Cancer patients on high-dose infusions are higher risk. Osteoporosis patients on annual zoledronic acid infusions or on denosumab injections sit in between, closer to the low end.
Can you get dental implants if you take oral bisphosphonates?
Usually, yes. Most surgeons place implants in patients on oral bisphosphonates for osteoporosis with informed consent about the small MRONJ risk, particularly when the patient has taken the drug for less than a few years. Risk rises with duration, so a patient who has taken alendronate for ten years is treated more cautiously than one who started last year. The guide to what disqualifies patients from dental implants lists bone medications among the conditions surgeons screen for and manage rather than refuse outright.
What the surgeon will ask
Which drug, what dose, how long, whether you have ever had an infusion, whether you also take steroids, and whether you have had any jaw surgery since starting the medication. Bring the answers in writing.
What the surgeon may do differently
Fewer implants per visit, gentler surgical technique, antibiotics around the procedure, an antibacterial rinse during healing, and a longer wait before loading. Some surgeons prefer to avoid grafting and sinus lifts in these patients where an alternative exists. The guide to bone grafting before implants covers the techniques that avoid it.
What about Prolia and other injectable or intravenous drugs?
Denosumab, sold as Prolia for osteoporosis, and zoledronic acid, sold as Reclast for osteoporosis, carry somewhat higher MRONJ risk than oral pills at the same indication, and most surgeons approach them with more caution. Denosumab has a practical wrinkle: its effect wears off within months of stopping, which makes timing surgery around the dosing schedule possible in a way it is not with bisphosphonates, which stay in bone for years.
Timing around denosumab
Many surgeons prefer to place implants toward the end of a six-month denosumab cycle, when the drug's effect is lowest, and to coordinate the next injection with the prescribing physician. Stopping denosumab without a plan is dangerous, because bone loss rebounds quickly, so this is a conversation between the surgeon and the physician, not a decision for the patient to make alone.
High-dose cancer treatment
Patients receiving zoledronic acid or denosumab at the higher doses used for bone metastases or multiple myeloma are at meaningfully higher MRONJ risk, and most surgeons avoid elective implant surgery in this group or defer it to specialists in a hospital setting. If you are in this group, the conversation starts with your oncologist.
Should you stop osteoporosis medication before dental implants?
Not on your own. Bisphosphonates persist in bone for years, so stopping them for a few months before surgery changes little and increases fracture risk. Some surgeons and physicians agree on a "drug holiday" for patients on long-term oral bisphosphonates, but the evidence that it reduces MRONJ risk is weak, and the fracture risk of stopping is real. Denosumab is different, as described above, and any pause has to be planned with the prescriber.
The right sequence is: tell the implant surgeon what you take, let the surgeon consult your physician, and follow the plan they agree on. A patient who quietly stops medication to get through surgery is trading a small jaw risk for a larger hip risk.
What are the signs of a problem after surgery on these medications?
Exposed bone in the mouth that does not heal within eight weeks, persistent pain or numbness at the surgical site, a bad taste or discharge, and a wound that opens after initially closing. Report any of these to the surgeon promptly. Early MRONJ is far more manageable than advanced MRONJ, and most cases in osteoporosis patients on oral drugs are mild and resolve with conservative care. The guide to the signs of a failing implant covers the symptoms that apply to any implant patient.
What should you ask at an implant consultation if you take these drugs?
Whether the surgeon has treated patients on your medication, what precautions they take, whether they will coordinate with your physician, and what they would do if a healing problem appeared. The answers separate a surgeon who understands the risk from one who either refuses all such patients or ignores the issue.
- Have you placed implants in patients on my specific medication, and how did those cases go?
- What is my MRONJ risk given my drug, dose, and duration?
- Will you coordinate the timing with my prescribing physician?
- What changes in your surgical plan for me: implant count, antibiotics, healing time, grafting?
- What are the signs I should report, and how quickly will you see me?
- Is there a technique that avoids grafting in my case?
Does osteoporosis itself affect dental implants?
Less than the medication does. Osteoporosis reduces bone density throughout the skeleton, including the jaw, but implant studies in osteoporotic patients not on bone medication show survival rates close to the general population. Lower density can affect initial stability at surgery, and surgeons compensate with implant design, longer healing before loading, and sometimes a different implant site.
What the scan shows
A CT scan reveals the density of the bone at the planned site, and a surgeon planning for an osteoporotic patient reads it with that in mind. Softer bone may call for a wider implant, a longer one, or an approach that avoids the softest regions.
Why the medication conversation dominates
The reason bone medication gets more attention than the disease is that MRONJ, while rare, is severe and hard to treat, and it is triggered by the surgery itself. Osteoporosis without medication raises no such risk. That is why the questions at the consultation are about the drug, the dose, and the duration rather than the diagnosis.
Which specialist should place implants for a patient on bone medication?
An oral surgeon or periodontist, in most cases. Both specialties see MRONJ in training and practice, both manage medically complex patients routinely, and both are more likely than a general dentist to coordinate with a physician and to recognize an early healing problem. For a patient on high-dose cancer treatment, a hospital-based oral surgeon is the usual referral. The guide to which specialist should place your implants explains the differences in training.
The Bottom Line
Osteoporosis medications slow jawbone healing and carry a small risk of a serious complication called MRONJ, which is rare in patients on oral bisphosphonates for osteoporosis, somewhat higher with denosumab and intravenous zoledronic acid, and meaningfully higher at the high doses used in cancer care. Most osteoporosis patients on standard treatment get implants with precautions and a surgeon who coordinates with their physician. Do not stop your medication on your own, bring the drug, dose, and duration to the consultation, and choose a specialist who has treated patients like you before. And when you are ready, find qualified providers near you at Dental Implant Directory.
Ready to find a qualified provider?
Search our independent directory of dental implant providers organized by specialty, location, and credentials. Find Providers Near You.
Ready to find a qualified provider?
Search our independent directory of dental implant providers organized by specialty, location, and credentials.